FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago; Luigi Formisano; Dejan Juric; Andrzej Niemierko; Alberto Servetto; Seth A. Wander; Laura M. Spring; Neelima Vidula; Jerry Younger; Jeffrey Peppercorn; Megan Yuen; Giuliana Malvarosa; Dennis C. Sgroi; Steven J. Isakoff; Beverly Moy; Leif W. Ellisen; A. John Iafrate; Carlos L. Arteaga; Aditya Bardia

doi:10.1158/1078-0432.ccr-19-0138

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

PURPOSE: . RESULTS: T47D cells induced resistance to fulvestrant that could be overcome by added TORC1 inhibition, but not PI3K or CDK4/6 inhibition. CONCLUSIONS: MBC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Drago et al. (2019) studied this question.

synapsesocial.com/papers/6a02d427bc3ffe278e652ac3 https://doi.org/10.1158/1078-0432.ccr-19-0138

View Full Paper

Ask AI

Bookmark

Share

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading